Inventor
BRANNETTI BARBARA
CH22 patents
⚠️ This page may combine multiple inventors who share the name “BRANNETTI BARBARA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
19 patentsUS9605070B2Mar 28, 2017
Antibody molecules to TIM-3 and uses thereof
NOVARTIS AG67 citations97
US10525083B2Jan 7, 2020
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG15 citations93
US10253086B2Apr 9, 2019
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG37 citations93
US10472419B2Nov 12, 2019
Antibody molecules to TIM-3 and uses thereof
NOVARTIS AG12 citations92
US9884913B2Feb 6, 2018
Antibody molecules to TIM-3 and uses thereof
NOVARTIS AG12 citations92
US9051365B2Jun 9, 2015
Antibodies that bind factor P
NOVARTIS AG18 citations90
US10981990B2Apr 20, 2021
Antibody molecules to TIM-3 and uses thereof
NOVARTIS AG11 citations85
US11149076B2Oct 19, 2021
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG9 citations84
US11155620B2Oct 26, 2021
Method of detecting TIM-3 using antibody molecules to TIM-3
NOVARTIS AG6 citations83
US11026976B2Jun 8, 2021
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG6 citations82
US12344657B2Jul 1, 2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG1 citations73
US11872249B2Jan 16, 2024
Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
NOVARTIS AG2 citations71
US9988440B2Jun 5, 2018
Compositions comprising antibodies targeting factor P
NOVARTIS AG2 citations71
US11111293B2Sep 7, 2021
IL-18 binding molecules
NOVARTIS AG1 citations68
US12594321B2Apr 7, 2026
Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer
NOVARTIS AG0 citations61
USRE49847EFeb 27, 2024
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG0 citations61
US12037378B2Jul 16, 2024
Variant CD58 domains and uses thereof
NOVARTIS AG1 citations59
US10889643B2Jan 12, 2021
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
NOVARTIS AG0 citations55
US10865237B2Dec 15, 2020
Nucleic acids encoding anti-Factor P antibodies
NOVARTIS AG0 citations50